IDbyDNA Participates in NIH National COVID-19 Genomics Consortium
May 7, 2020
The CDC is leading the national SARS-CoV-2 Sequencing for Public Health Emergency Response, Epidemiology and Surveillance initiative (SPHERES) to coordinate SARS-CoV-2 sequencing across the U.S. Utah’s own IDbyDNA will be participating in the effort along with clinical and public health laboratories, academic institutions, and other private sector companies. The SPHERES consortium aims to generate information about the virus that will strengthen COVID-19 mitigation strategies.
In addition to IDbyDNA, corporate participants include Abbott Diagnostics, BioMérieux, Color, Ginkgo Bioworks, Illumina, In-Q-Tel, LabCorp, One Codex, Oxford Nanopore Technologies, Pacific Biosciences, Qiagen, Quest Diagnostics, and Verily Life Sciences.
Recent News
- RefloDx Closes $2 Million Seed Round to Advance Noninvasive Testing for Chronic Throat and Voice Symptoms
- Myriad Genetics Releases New MONSTAR-SCREEN-3 Data Demonstrating the Potential of Ultra-Sensitive MRD Detection in Colorectal and Pancreatic Cancers
- Ultragenyx sells second rare pediatric PRV in a week for $203M
- Co-Diagnostics’ Joint Venture CoMira Diagnostics Invited by Saudi Ministry to Participate in Strategic Manufacturing Forum
- Route 92 Medical Announces $100 Million Corporate Debt Facility
- Myriad Genetics and Labcorp Announce Definitive Agreement for Myriad to Sell Prenatal Health Testing Business to Labcorp
